Hans Matter

This inventor holds 54 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 24 EPO patents, primarily in Pharmaceutical Chemistry (CPC class C07D). Top assignees: Sanofi-A Ventis Deutschland Gmbh, Sanofi-Aventis, Aventis Pharma Deutschland, Gmbh. Active years: 2002-2026.

USPTO Granted Patents = 54 (Patent Applications = 10)

% Patents Active = 31.5

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 24 (Patent Applications = 20)

Average Co-Inventor Count = 6.0

ph-index = 10

Forward Citations = 414(Granted Patents)

Forward Citations (Not Self Cited) = 377(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Langenselbold, DE (2002 - 2012)
Frankfurt-am-Main, DE (2009 - 2024)

Company Filing History:

18 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

RIPK1 Inhibitors

Cyclic Peptides

SCD Inhibitors

Oxadiazolone Derivatives

Factor Xa Inhibitors

Matrix Metalloproteinase Inhibitors

Sulfonamides

Pyridazinone Derivatives

Pharmaceutical Compositions

Amino Acid Derivatives

Thiadiazole Compounds

Antithrombotic Activity

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655139 - Isoxazolidines as RIPK1 inhibitors and use thereof (2026-06-16),

2. 11897876 - Isoxazolidines as RIPK1 inhibitors and use thereof (2024-02-13),

3. 9073975 - Cyclic peptides, their preparation and their use as inhibitors of the platelet adhesion (2015-07-07),

4. 8946212 - Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals (2015-02-03),

5. 8716317 - Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals (2014-05-06),

6. 8673917 - 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors (2014-03-18),

7. 8580813 - Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals (2013-11-12),

8. 8415336 - Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals (2013-04-09),

9. 8344004 - Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals (2013-01-01),

10. 8329725 - Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals (2012-12-11),

11. 8211885 - Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals (2012-07-03),

12. 8153647 - Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics (2012-04-10),

13. 8143242 - Malonamide derivatives with antithrombotic activity (2012-03-27),

14. 8088925 - Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors (2012-01-03),

15. 8039481 - Tetrahydrofuran derivatives for use as inhibitors of matrix metalloproteinases (2011-10-18),

Title: Hans Matter - Innovative Inventor from Langenselbold

Introduction: Hans Matter is a renowned inventor hailing from Langenselbold, Germany, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Hans Matter holds several patents in the areas of renewable energy, sustainable materials, and advanced robotics, showcasing his commitment to creating a more efficient and eco-friendly world.

Career Highlights: With over two decades of experience in research and development, Hans Matter has worked for leading tech companies and research institutions, spearheading projects that have revolutionized industries.

Collaborations: Throughout his career, Hans Matter has collaborated with top engineers, scientists, and designers from around the globe, fostering a culture of innovation and excellence in all his endeavors.

Conclusion: Hans Matter's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and researchers worldwide.